Toronto, December 1, 2022 /PRNewswire/ – Nurosene Health Inc. (“Nurosene” or “we”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF) is a company focused on becoming a leader in the development of artificial intelligence (AI) / Machine Learning (ML) Solutions for the Pharmaceutical Industry is pleased to share the following business updates.
“Nurosene has made the strategic decision to focus on the continued development and deployment of next-generation products that will benefit companies, particularly in the pharmaceutical industry, utilizing technology developed by NetraMark (our wholly-owned subsidiary). Specifically, the NetraAI platform will extract insights from patient data leading to predictive patient enrichment strategies to de-risk the clinical trial process.As we move forward, Our main focus is to support this decision.” – George Achilleos, CEO of Nurosene.
Summary points to support strategic decision making
Industry Issues – The pharmaceutical industry faces two major challenges that could benefit from the use of AI.
- Problem 1 – Novel Molecule Discovery – Identifying molecules that address disease is a real challenge. The majority of life science AI technology companies focus on the field of molecular identification, which involves the ingestion of large biological data sets run through AI algorithms with the goal of helping discover new molecules. .
- Issue 2 – Conducting Clinical Trials – Once a molecule is identified, the success rate of getting through the clinical trial process is very low. In fact, less than 12% of drug candidates advancing to Phase 1 clinical trials are approved for commercial use.
Opportunity – Nurosene sees a huge opportunity to address the extremely low success rate in the clinical trial process using NetraAI technology. This market is robust, growing, and large. Nearly 5,000 interventional clinical studies2 have been initiated in the last 12 months alone. In addition, Phases 1, 2 and 3 have spent more than US$40 billion3.
Challenge – Few companies have been able to apply AI techniques to derisk clinical trials. This is primarily due to the small data sets that exist in most clinical trials, regardless of phase. In fact, more than 90% of his clinical trials initiated between 1999 and 2021 had fewer than his 1,000 participants. This suggests that traditional AI methods are statistically unresponsive to small data sets that can lead to statistically significant insights that can be used to enrich clinical trial patient recruitment plans. In points, it presents its own challenges.
Solution – NetraAI technology has been in development over the last five years and is a model that can extract insights from small datasets to shed light on different aspects of how patients relate to each other / It has the intent and the ability to create a mosaic of hypotheses. Others on the given display. This ultimately reveals a hypothesis about which set of genetic traits best associates and responds to the drug in question.
In addition, we have developed specific product and support sales materials to initiate aggressive commercialization efforts. To support this, we have put in place a management team with deep pharmaceutical industry experience. Specifically, as previously announced, we have hired the following key individuals to accelerate our business plan goals:
Josh Spiegel – NetraMark President – Mr. Spiegel has over 25 years of experience in finance, sales and corporate strategy, with a strong background in healthcare, business services and technology. Prior to joining NetraMark, Spiegel was Vice President of Business Strategy for his VeraSci, where he used his experience to strategically plan and oversee commercial operations, including the launch of the Pathway eClinical platform, and grow the company. We have positioned it to be extremely successful. A leader in the pharmaceutical services sector, he announced his $330 million (US) exit to WCG Clinical.
“We believe there is a great opportunity to innovate on the traditional methods used to derive patient enrichment criteria for clinical trials. We use small datasets to drive statistically significant patient insights. The underlying NetraAI algorithms used to do so are very compelling.” – Josh Spiegel, NetraMark President.
Dr. Luca Pani – Chief Innovation and Regulatory Officer – Dr. Pani is an academic from both the University of Miami, USA and the University of Modena, Italy, and former Director General of the Italian Medicines Agency (AIFA) (2011-2016) ), where he managed a multi-billion dollar budget for drug spending and negotiations on behalf of the Italian National Health System. Dr. Pani is Vice President of Regulatory Strategy and Market Access Innovation at VeraSci and provided scientific strategic planning for the FDA (U.S. Food and Drug Administration) accreditation program for the Pathway eClinical platform.
Dr. DJ Cook – Chief Medical Officer – DJ Cook, MD, PhD, is a neurosurgeon and neuroscientist at Queen’s University and serves as Director and Chair of the Department of Neurosurgery. Dr. Cook received his M.D., Ph.D., and residency from the University of Toronto and a fellowship in cerebrovascular and skull base surgery at Stanford University for his training. Dr. Cook’s current research focuses on the development of predictive imaging, physiological and behavioral biomarkers in stroke and traumatic brain injury. His research includes the use of multi-sequence his MRI analysis with artificial intelligence algorithms to derive new insights into disease mechanisms and monitor recovery and treatment.
For more information, including projected earnings guidance, please refer to our latest updated investor presentation on our investor page at https://nurosene.com/investors.
Nurosene is a company focused on becoming a leader in developing artificial intelligence (AI) / machine learning (ML) solutions for the pharmaceutical industry.
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws, including the Company’s future strategic focus, novel molecule discovery and clinical trials. including our views on the challenges, and opportunities to address, in the pharmaceutical industry. the low success rate of the clinical trial process using NetraAI technology, the potential market size, the intentions and capabilities of NetraAI technology and the data it may generate, our commercialization efforts and our business; Suggestions for accelerating the plan. Current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information is classified as “expect,” “likely,” “may,” “will,” “should,” “intend,” “anticipate,” and “possible.” “could”, “proposed”, “estimate”, and other similar words, including negative and grammatical variations thereof, or that certain events or conditions “could occur”, ” Forward-looking information includes estimates, plans, expectations, opinions, projections, projections, goals, guidance or other statements that are not statements of fact. Includes a description. Forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other material risks that could cause our actual results or industry results to differ materially from future results, performance or achievements. affected by various factors. Forward-looking information speaks only as of the date it is made and, except as required by law, Nurosene does not intend to update or update any forward-looking information as a result of new information, future results. We are not obligated to make corrections. event, or otherwise. New factors emerge from time to time and it is impossible for Nurosene to predict all such factors.
In reviewing these forward-looking statements, readers should be aware of the risk factors and other cautionary statements set forth in the materials filed with applicable Canadian securities regulators on SEDAR at www.sedar.com. there is. For the year ended September 30, 2021 and risk factors set forth in company presentations. These and other risks could cause actual events or results to differ materially from those set forth in the forward-looking information.
CSE does not take responsibility for the adequacy or accuracy of this release.
1 Source: PhRMA adaptation of DiMasi JA et al12.Tufts CSDD13; FDA142 Source: https://clinicaltrials.gov/3PhRMA Membership Survey 20214https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial -registrations-by-year-location-disease-and-developmental stage
View original content: https://www.prnewswire.com/news-releases/nurosene-business-update-301692034.html
SOURCE Nurosene Health Inc.